PERBANDINGAN PANDUAN NASIONAL TATALAKSANA TUBERKULOSIS TAHUN 2014 DI INDONESIA DAN PANDUAN TERBARU TERAPI UNTUK TERDUGA TB MENURUT WHO TAHUN 2017
Article Sidebar
Published:
May 9, 2021
Main Article Content
Article Details
How to Cite
Baharuddin, R. (2021). PERBANDINGAN PANDUAN NASIONAL TATALAKSANA TUBERKULOSIS TAHUN 2014 DI INDONESIA DAN PANDUAN TERBARU TERAPI UNTUK TERDUGA TB MENURUT WHO TAHUN 2017. JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia, 6(1), 104-111. Retrieved from https://bapin-ismki.e-journal.id/jimki/article/view/393
Section
Editorial
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
1. Kementerian Kesehatan Republik Indonesia.2016. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.02.02/Menkes/305/2014 tentang Pedoman Nasional Pelayanan Kedokteran Tatalaksana Tuberkulosis. Kementerian Republik Indonesia 2016.
2. Perhimpunan Dokter Paru Indonesia. 2003. Pedoman Diagnosis dan Penatalaksanaan Tuberkulosis di Indonesia. Perhimpunan Dokter Paru Indonesia 2013.
3. World Health Organization. 2017. Global Tuberculosis Report 2017. France : World Health Organization.
4. Pusat Data dan Informasi Kementerian Kesehatan Indonesia. 2016. Tuberkulosis : Temukan Obati Sampai Sembuh. Pusat Data dan
Informasi Kementerian Kesehatan Indonesia.
5. Kementerian Kesehatan Republik Indonesia Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan. 2011. Stop TB Terobosan Menuju Akses Universal Strategi Nasional Pengendalian TB di Indonesia. Kementerian Kesehatan Republik Indonesia Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan 2011.
6. Pusat Data dan Informasi Kementerian Kesehatan RI 2017. Data dan pnformasi Profil Kesehatan Indonesia 2016. Kementerian Kesehatan Republik Indonesia.
7. Kementerian Kesehatan Republik Indonesia Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan. 2014. Stop TB Pedoman Nasional PengendalianTuberkulosis. Jakarta: Kementerian Kesehatan Republik Indonesia Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan 2014.
8. World Health Organization.2017. Treatment of Tuberculosis : Guideline for Treatment of Drug Susceptible Tuberculosis and Patient Care Update 2017. World Health Organization.
9. Tamsil Tamam A., Arifin Nawas, Dianiati Kusumo Sutoyo. 2014. Pengobatan Multidrugs Resistant Tuberculosis (MDR-TB) dengan Paduan Jangka Pendek. Jakarta : Departemen Pulmonologi dan Ilmu Kedokteran Respirasi Fakultas Kedokteran Universitas Indonesia
10. Chen Tun Chieh, et al. 2010. Floroquinolone are associated with delayed treatment and resistance in Tuberculosis : a systematic review and meta-analysis. New York : International Journal of Infectious Disease 15 (2011): p.215
11. Hogan Catherine A, et al. 2016. Impact of Fluoroquinolone Treatment on Delay of Tuberculosis Diagnosis: A Systematic Review and Meta-Analysis.Journal of Clinical Tuberculosis and other Mycobacterial Diasease 6 (2017) : p.5
12. Takiff Howard dan Elba Guerrero. 2011. Minireview :Current Prospects for the Florokuinolon as the First-Line Tuberculosis Therapy. American Society for Microbiology Vol 55 No.12 : p.5421-5429
13. Al-Shaer Mohammad H, et al. 2017. Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. BMC Infectious Disease (2017) 17:118 p.3-5
14. American Thoracic Society, CDC, and Infectious Disease Society of America. 2003. Morbidity and Mortality Weekly Report : Treatment of Tuberculosis . Department of Health and Human Services Center for Disease Control and Prevention : p.25
15. Kautsar Angga P., Tina A.Intani. 2016. Kepatuhan dan Efektifitas Obat Anti Tuberkulosis (OAT) Kombinasi Dosis Tetap (KDT) dan Tunggal pada Pnederita Tb Paru Anak di Salah Satu Rusah Sakit di Kota Bandung. Jurnal Farmasi Klinik Indonesia Volume 5 Nomo 3 (2016) : p.221
16. Mandal Pranab Kumal, Abhijit Mandal,SujitKumal Bhattacharyya. 2013. Comparing the Daily Versus the Intermiten Regimens of the Anti-Tubercular Chemotherapy in the Initial Intensive Phase in Non-HIV, Sputum Positif, Pulmonary Tuberculosis Patients. Journal of Clinical and Diagnostic Research 2013 February Vol-7(2): p.292-295
17. Kasozi Samuel, Justin Clark, dan Suhail A.R. Doi. 2015. “Intermiten Versus Daily Pulmonary Tuberculosis Treatment Regimens : A Meta Analysis. Marshfield Clinic Health System.
2. Perhimpunan Dokter Paru Indonesia. 2003. Pedoman Diagnosis dan Penatalaksanaan Tuberkulosis di Indonesia. Perhimpunan Dokter Paru Indonesia 2013.
3. World Health Organization. 2017. Global Tuberculosis Report 2017. France : World Health Organization.
4. Pusat Data dan Informasi Kementerian Kesehatan Indonesia. 2016. Tuberkulosis : Temukan Obati Sampai Sembuh. Pusat Data dan
Informasi Kementerian Kesehatan Indonesia.
5. Kementerian Kesehatan Republik Indonesia Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan. 2011. Stop TB Terobosan Menuju Akses Universal Strategi Nasional Pengendalian TB di Indonesia. Kementerian Kesehatan Republik Indonesia Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan 2011.
6. Pusat Data dan Informasi Kementerian Kesehatan RI 2017. Data dan pnformasi Profil Kesehatan Indonesia 2016. Kementerian Kesehatan Republik Indonesia.
7. Kementerian Kesehatan Republik Indonesia Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan. 2014. Stop TB Pedoman Nasional PengendalianTuberkulosis. Jakarta: Kementerian Kesehatan Republik Indonesia Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan 2014.
8. World Health Organization.2017. Treatment of Tuberculosis : Guideline for Treatment of Drug Susceptible Tuberculosis and Patient Care Update 2017. World Health Organization.
9. Tamsil Tamam A., Arifin Nawas, Dianiati Kusumo Sutoyo. 2014. Pengobatan Multidrugs Resistant Tuberculosis (MDR-TB) dengan Paduan Jangka Pendek. Jakarta : Departemen Pulmonologi dan Ilmu Kedokteran Respirasi Fakultas Kedokteran Universitas Indonesia
10. Chen Tun Chieh, et al. 2010. Floroquinolone are associated with delayed treatment and resistance in Tuberculosis : a systematic review and meta-analysis. New York : International Journal of Infectious Disease 15 (2011): p.215
11. Hogan Catherine A, et al. 2016. Impact of Fluoroquinolone Treatment on Delay of Tuberculosis Diagnosis: A Systematic Review and Meta-Analysis.Journal of Clinical Tuberculosis and other Mycobacterial Diasease 6 (2017) : p.5
12. Takiff Howard dan Elba Guerrero. 2011. Minireview :Current Prospects for the Florokuinolon as the First-Line Tuberculosis Therapy. American Society for Microbiology Vol 55 No.12 : p.5421-5429
13. Al-Shaer Mohammad H, et al. 2017. Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. BMC Infectious Disease (2017) 17:118 p.3-5
14. American Thoracic Society, CDC, and Infectious Disease Society of America. 2003. Morbidity and Mortality Weekly Report : Treatment of Tuberculosis . Department of Health and Human Services Center for Disease Control and Prevention : p.25
15. Kautsar Angga P., Tina A.Intani. 2016. Kepatuhan dan Efektifitas Obat Anti Tuberkulosis (OAT) Kombinasi Dosis Tetap (KDT) dan Tunggal pada Pnederita Tb Paru Anak di Salah Satu Rusah Sakit di Kota Bandung. Jurnal Farmasi Klinik Indonesia Volume 5 Nomo 3 (2016) : p.221
16. Mandal Pranab Kumal, Abhijit Mandal,SujitKumal Bhattacharyya. 2013. Comparing the Daily Versus the Intermiten Regimens of the Anti-Tubercular Chemotherapy in the Initial Intensive Phase in Non-HIV, Sputum Positif, Pulmonary Tuberculosis Patients. Journal of Clinical and Diagnostic Research 2013 February Vol-7(2): p.292-295
17. Kasozi Samuel, Justin Clark, dan Suhail A.R. Doi. 2015. “Intermiten Versus Daily Pulmonary Tuberculosis Treatment Regimens : A Meta Analysis. Marshfield Clinic Health System.